Blog
How it works
Services
Sign In
Homepage
Blog
How it works
Services
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
FULC.US
id: 604, Created by Stan Vick Chase, Scout

Join Fulcrum Therapeutics (FULC) Misleading Case to Fight Losses

  • Fulcrum disclosed the FDA's full clinical hold on FTX-605.
  • Fulcrum's stock price fell 56%, seriously damaging investors.
  • Investors may suspect the Company, Its Leaders or its Service Providers of misleading.
On February 24, 2023, Fulcrum disclosed that "the FDA verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug (IND) application for FTX-6058 for the potential treatment of sickle-cell disease. The Agency indicated that it would provide a formal Clinical Hold Letter to the company within 30 days."

On February 24, 2023, Fulcrum's stock price fell 56%, seriously damaging investors.

Taking all representations, Investors may have reasons to suspect the Company, Its Leaders or its Service Providers of misleading statements o fail to timelly diclose the truth about business prospects.
Alleged Offence
Mismanagement
Misleading Statements
Failure to Disclose
Negligence
Omissions
Suspected Party
Directors
Management
Government Authority
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
24 February 2023
Collecting participants…
Created by Stan Vick Chase, Scout

Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unm...

    Ticker
    FULC.US
    ISIN
    US3596161097
    CIK
    1680581
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    26 Landsdowne Street, Cambridge, MA, United States, 02139